Amid the “hidden pandemic" of antibiotic-resistant infections, Day Zero Diagnostics is doubling down on its mission of developing tools to identify and profile those bacterial diseases as early as possible.
The money keeps flowing into Ventus Therapeutics. Just 10 months after raising one mega-round, the undruggable target specialist has banked a further $140 million as it prepares to file three INDs next year.
While the U.K. shattered its previous biotech venture capital funding record by 81% in 2021, the continental Europe saw private financing dip by about 12%. Genetic sequencing startup Oxford Nanopore and artificial intelligence drug discoverer Exscientia led the way in both VC fundraising and initial public offering proceeds.
Gilead has tagged along on Kyverna Therapeutics’ journey as a startup since the beginning, and now the Big Pharma has helped stock up the cell therapy biotech in an $85 million financing round to prepare for a launch into the clinic this year.